supp.ai
Discover Supplement-Drug Interactions
Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 3 years ago
drug:
Suramin
supplement:
Sphingosine 1-Phosphate
Research Papers that Mention the Interaction
“Furthermore, suramin , which selectively blocks S1P(3) receptors, inhibited the vasoconstrictor effect of S1P , indicating that S1P(3) receptors account for at least part of S1P-mediated vasoconstriction in cerebral arteries.”
“In vivo, intracarotid injection of S1P decreased cerebral blood flow, an effect prevented by suramin treatment.”
S1P3 receptors mediate the potent constriction of cerebral arteries by sphingosine-1-phosphate.“Moreover, activation of I(K.ACh) by SPP was blocked by the Edg-3-selective antagonist suramin , which did not affect basal or carbachol-stimulated K(+) currents.”
“Furthermore, the effect of S1P was mimicked by SEW2871 (an S1P(1) agonist), and blocked by suramin (an S1P(3) antagonist) and by silencing S1P(1,3) expression.”
“Inhibition of S1P receptors by suramin (inhibitor of S1P3), JTE013 (inhibitor of S1P2) or VPC23019 (inhibitor of S1P1 and S1P3) reduced the up-regulation of Cox-2 induced by HDL and S1P.”
“In the presence of the S1P and LPA receptor antagonist suramin , gpr3-, gpr6- and gpr12-mediated intracellular Ca(2+) mobilization via S1P is enhanced.”
“5 The S1P3 receptor antagonist suramin (100 microM) significantly inhibited responses to S1P and SPC in rats but not in mice, and did not affect noradrenaline responses in either species.”
Comparison of noradrenaline and lysosphingolipid-induced vasoconstriction in mouse and rat small mesenteric arteries.“ Suramin (200 μM) significantly reduced, by ∼90%, the effects of S1P on ICM and ICa, suggesting that most of S1P action occurred via Edg-3Rs.”
Help us improve supp.ai, we'd love to hear your feedback: Submit Feedback